GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Shanghai Pioneer Holding Ltd (HKSE:01345) » Definitions » Debt-to-EBITDA

Shanghai Pioneer Holding (HKSE:01345) Debt-to-EBITDA : 0.41 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Shanghai Pioneer Holding Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shanghai Pioneer Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$67 Mil. Shanghai Pioneer Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$14 Mil. Shanghai Pioneer Holding's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$200 Mil. Shanghai Pioneer Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.41.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Shanghai Pioneer Holding's Debt-to-EBITDA or its related term are showing as below:

HKSE:01345' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07   Med: 0.3   Max: 1.9
Current: 0.41

During the past 12 years, the highest Debt-to-EBITDA Ratio of Shanghai Pioneer Holding was 1.90. The lowest was 0.07. And the median was 0.30.

HKSE:01345's Debt-to-EBITDA is ranked better than
82.9% of 427 companies
in the Healthcare Providers & Services industry
Industry Median: 2.63 vs HKSE:01345: 0.41

Shanghai Pioneer Holding Debt-to-EBITDA Historical Data

The historical data trend for Shanghai Pioneer Holding's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Pioneer Holding Debt-to-EBITDA Chart

Shanghai Pioneer Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.14 0.07 0.12 0.37

Shanghai Pioneer Holding Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.24 0.13 0.54 0.41

Competitive Comparison of Shanghai Pioneer Holding's Debt-to-EBITDA

For the Pharmaceutical Retailers subindustry, Shanghai Pioneer Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Pioneer Holding's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Shanghai Pioneer Holding's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Shanghai Pioneer Holding's Debt-to-EBITDA falls into.



Shanghai Pioneer Holding Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Shanghai Pioneer Holding's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(67.018 + 13.943) / 220.808
=0.37

Shanghai Pioneer Holding's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(67.018 + 13.943) / 199.576
=0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Shanghai Pioneer Holding  (HKSE:01345) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Shanghai Pioneer Holding Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Shanghai Pioneer Holding's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Pioneer Holding (HKSE:01345) Business Description

Traded in Other Exchanges
N/A
Address
No.15, Lane 88 Wuwei Road, Putuo District, Shanghai, CHN, 200331
Shanghai Pioneer Holding Ltd is an investment holding company. It is engaged in the marketing, promotion, sales, and channel management service for pharmaceutical products and medical devices in China. The company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology, and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, orthopedics, odontology, and wound care. The majority of its revenue derives from the Sales of pharmaceutical products segment. The group operates mainly in PRC.

Shanghai Pioneer Holding (HKSE:01345) Headlines

No Headlines